pharmaphorum

SEPTEMBER 4, 2020

The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics. This has gained a lot of attention in recent years due to revolutionary breakthroughs in debilitating chronic diseases such as cancer.

Medicine 59

Medicine Production Genetic Engineering Genetics 59

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome’s diagnostic searches for direct indication of tumors and signs of the immune system’s response, integrating genomics, transcriptomics, methylomics, and proteomics technologies.

Vaccine 53

Vaccine Vaccination Research Trials 53

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. The team obtained sequences from the newly circulating B.1.1.7 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccine 52

Vaccine Vaccination Research Immune Response 52

Cloudbyz

JULY 31, 2024

This includes tracking the persistence and function of modified cells, detecting any adverse immune responses, and ensuring that the therapeutic effects are sustained over time. Post-Treatment Monitoring: After treatment, diagnostics play a vital role in monitoring patients for potential side effects and long-term efficacy.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

Roots Analysis

OCTOBER 30, 2023

Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest. This allows generation of multiple copies of the gene of interest at the target owing to the amplification property of the template.

RNA 40

RNA Vaccine Vaccination Development 40

The Pharma Data

JANUARY 4, 2021

Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. Chimeric PD-1-expressing T-cells engage with the PD-1 ligands on the surface of the cancer cells and this interaction activates the T-cells to directly kill the tumor cells. About Longwood University. About Kiromic.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccine 40

Vaccine Vaccination Development Medicine 40

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

pharmaphorum

APRIL 28, 2021

“Text mining was also able to highlight new insights into the mechanisms of pancreatic cancer’s immune evasion, which refers to cancer cells’ ability to evade an immune response” . Figure 1: Trending ‘Protein and Genomic’ terms with a semantic relationship to pancreatic cancer.

Immune Response 105

Immune Response Life Science Genome Genomics 105

pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

DNA 52

DNA Immune Response Genome Genomics 52

XTalks

NOVEMBER 30, 2023

These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs).

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

APRIL 8, 2021

The Company will share a Spotlight Theater Presentation: The Orchestrated Immune Response: Dynamic Forces Guiding Cancer Immunity , introducing a novel framework for understanding the role of the immune system in cancer, with the potential to reshape the way scientists develop medicines to counteract tumour growth.

DNA 52

DNA Medicine Genome Genomics 52

pharmaphorum

SEPTEMBER 22, 2022

The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

Vaccine 97

Vaccine Vaccination Antibody Clinical Trials 97

The Pharma Data

AUGUST 24, 2020

They say genome sequencing shows the two strains of the virus are “clearly different”, making it the world’s first proven case of reinfection. Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. Getty Images.

Immune Response 52

Immune Response Genome Project Genome Genomics 52

Delveinsight

DECEMBER 13, 2020

HBV DNA can be integrated into the host genome. Hence, the persistence of cccDNA, the presence of integrated HBV DNA, and impaired innate and adaptive immune responses make it difficult to eliminate HBV from chronically infected patients. There are additional barriers to eliminating HBV.

Genotype 52

Genotype FDA Approval DNA Drugs 52

pharmaphorum

NOVEMBER 24, 2020

Another is the delivery of molecule switches to CAR-NK cells, used to activate biological pathways that can help overcome the immunosuppressive microenvironment around tumours and improve recruitment of other elements of an immune response.

Engineer 52

Engineer Immune Response DNA Genome 52

The Pharma Data

JUNE 19, 2022

Known as “the guardian of the genome,” p53 is a class of proteins tasked with suppressing tumor development. He said that therapies that can increase natural killer cell infiltration and/or activation in tumors are urgently needed. They conducted their first experiment with cultured mouse melanoma cells.

Drugs 52

Drugs Protein Immune Response Scientist 52

The Pharma Data

DECEMBER 31, 2020

“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

JUNE 30, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Genome Genomics Containment 52

The Pharma Data

APRIL 11, 2021

The scientific rationale for using immunotherapy in the neoadjuvant setting is twofold: it presents the earliest opportunity to treat cancer cells that have spread in the body without detection, and the presence of a tumor during immunotherapy treatment may enable a stronger immune response, potentially making the treatment more effective.

Trials 52

Trials Immune Response Genome Genomics 52

The Pharma Data

MARCH 26, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

HR 52

HR Protein Genome Genomics 52

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. This is reminiscent of influenza, another respiratory disease that requires repeated vaccinations due to its genomic instability resulting in modifications of the surface protein hemagglutinin.

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

The Pharma Data

MAY 4, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

Protein 52

Protein HR In-Vitro Medicine 52

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

DECEMBER 30, 2020

The Phase I/II study results, together with recently generated preclinical data, indicate that ARCT-021 leads to a potent immune response to SARS-CoV-2, and demonstrates a differentiated biological profile whereby the immune response increases in the weeks following vaccination, the company said.

Genome 52

Genome Genomics Immune Response Vaccine 52

The Pharma Data

OCTOBER 14, 2020

Additionally, immunogenicity, duration of immune response and occurrence of symptomatic COVID-19 will be measured. The study’s primary objective is to examine the safety and reactogenicity of two-doses of the vaccine. Cohort 2 (n = 10): Prime (Day 1) + Boost (Day 22) at 1 × 10 11 VP per dose.

Antibody 40

Antibody Vaccine Vaccination Trials 40

pharmaphorum

JANUARY 6, 2023

BioNTech gets the opportunity to tap into the NHS as a source of subjects for its cancer vaccine studies, as well as access to genomics and health data resources, and in return will open an R&D centre in Cambridge, employing more than 70 scientists, as well as an office in London. It will also cover some infectious disease targets.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccine 111

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 28, 2021

BioNTech said in a statement that it is waiting on more data from lab tests, due in the next couple of weeks, to see if Omicron could be an “escape variant” – a strain of SARS-CoV-2 that could evade the immune responses stimulated by current vaccines.

Vaccine 111

Vaccine Vaccination Protein Genetics 111

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccine 52

Vaccine Vaccination In-Vivo Genetics 52

The Pharma Data

JANUARY 11, 2021

Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. TIGIT and PD-L1 are proteins that play a role in suppression of the immune system.

Medicine 52

Medicine Immune Response Protein Gene 52